OVA1 Products Testing Resources
Incorporate Ultrasound into Your OVA1® Test Result Interpretation
Combining OVA1 (MIA) with powerful tools like ultrasound can aid in the detection of ovarian cancer. According to a study by Goodrich et al., imaging and the OVA1 (MIA) score work together to better identify patients at higher risk of malignancy.
Patients with an elevated risk of malignancy may benefit from a consultation with a gynecologic oncologist.
In the prospective study, Bristow, et al. published a histogram showing the observed risk of malignancy associated with respective OVA1 (MIA) scores for premenopausal and postmenopausal women5:
Risk of Malignancy
The OVA1 (MIA) and OVERA (MIA2) test scores are reported as a single numeric score on a scale of 0-10.
For premenopausal women, a result of greater than or equal to 5, is associated with an elevated risk of malignancy. Results between 5.0-7.0 will be reflexed to OVERA. For postmenopausal women, an OVA1 (MIA) score of greater than or equal to 4.4 is associated with an elevated risk for malignancy. Results between 4.4-6.0 will be reflexed to OVERA. OVERA results are reported with a score of <5.0 as Low Risk and ≥5.0 as Elevated Risk.
Risk of malignancy was reported as below 1.4% for premenopausal women and 3.3% for postmenopausal women.
Higher risk of malignancy – see graph to the left for representative data from published clinical trial.
Test Performance Measures
Learn about the terminology and performance measures to determine the accuracy of a diagnostic test:
High sensitivity is often determined as the most critical measure of a test because it minimizes the number of patients with the disease that are missed. A highly sensitivity test is generally associated with a strong negative predictive value; this gives providers confidence that a negative test result likely suggests a patient is truly without the disease.
- Sensitivity: The percent of patients with a malignant mass who had a positive test result
- Specificity: The percent of patients with a benign mass who had a negative test result
- Negative predictive value: The percent of patients with a negative test result who had a benign mass
- Positive predictive value: The percent of patients with a positive test result who had a malignant mass
- False positive: The percent of patients with a positive test result who had a benign mass
- False negative: The percent of patients with a negative test result who had a malignant mass
For Providers: Understand Your OVA1 Test Results
Schedule Your Discussion
For question interpreting test results, physicians can now speak directly with the Aspira Labs Clinical Team, including our Laboratory Director, Dr. Fritsche and our Global Medical Director Dr. Charles Dunton, MD Gynecologic Oncologist. We hope this clinical discussion will help you better understand the OVA1plus test results and assess the best treatment plan for your patients.
- Carney ME, et al., Gynecol Oncol. 2002 Jan;84(1):36-42.
- Earle CC, et al., J Natl Cancer Inst. 2006 Feb 1;98(3):172-80
- Ueland, FR et al., Gynecol Oncol. 2005 Nov;99(2):400-3
- Goodrich ST, et al., Am J Obstet Gynecol. 2014 Jul;211(1):65.e1-65.e11
- Bristow RE, et al., Gynecol Oncol. 2013;128:252-259
- Timmerman D, et al., Ultrasound Obstet Gynecol 1999;13:11–16
- Levine D, et al., Ultrasound Q. 2010 Sep;26(3):121-31.
- Ueland FR, et al., Obstet Gynecol. 2011;117(6):1289-1297
- Longoria TC, et al., Am J Obstet Gynecol. 2014 Jan;210(1):78.e1-9
- Moss EL, et al., J Clin Pathol. 2005 Mar; 58(3): 308–312.
- Petignat P, et al., Eur J Cancer. 2000 Oct;36(15):1933-7.
- Bristow RE, et al., Am J Obstet Gynecol. 2013 Dec;209(6):581.e1-8
- American Congress of Obstetricians and Gynecologists, Practice Bulletin 174; 2016 Nov